Corcept Therapeutics Faces Securities Fraud Lawsuit Over Misleading FDA Claims
Schall Law Firm seeks investors in $COPT securities class action, alleging false statements about relacorilant FDA approval prospects between October 2024 and December 2025.
CORTsecurities fraudclass action lawsuit
